WO1995024923A3 - Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens - Google Patents

Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens Download PDF

Info

Publication number
WO1995024923A3
WO1995024923A3 PCT/US1995/003311 US9503311W WO9524923A3 WO 1995024923 A3 WO1995024923 A3 WO 1995024923A3 US 9503311 W US9503311 W US 9503311W WO 9524923 A3 WO9524923 A3 WO 9524923A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide complexes
stress protein
prophylactic
vaccines against
therapeutic vaccines
Prior art date
Application number
PCT/US1995/003311
Other languages
French (fr)
Other versions
WO1995024923A2 (en
Inventor
Pramod K Srivastava
Heiichiro Udono
Nathalie E Blachere
Original Assignee
Sinai School Medicine
Pramod K Srivastava
Heiichiro Udono
Nathalie E Blachere
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22782837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1995024923(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinai School Medicine, Pramod K Srivastava, Heiichiro Udono, Nathalie E Blachere filed Critical Sinai School Medicine
Priority to US08/704,727 priority Critical patent/US6048530A/en
Priority to AT95913733T priority patent/ATE286744T1/en
Priority to EP19950913733 priority patent/EP0750513B1/en
Priority to AU21009/95A priority patent/AU701732B2/en
Priority to DK95913733T priority patent/DK0750513T3/en
Priority to DE1995633920 priority patent/DE69533920T2/en
Priority to JP52418795A priority patent/JPH10501520A/en
Publication of WO1995024923A2 publication Critical patent/WO1995024923A2/en
Publication of WO1995024923A3 publication Critical patent/WO1995024923A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/823—Immunogenic carrier or carrier per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Abstract

Disclosed is a family of vaccines that contain stress protein-peptide complexes which when administered to a mammal are operative to initiate in the mammal a cytotoxic T cell response against cells infected with a preselected intracellular pathogen. Also disclosed are methodologies for preparing and administering vaccines containing such stress protein-peptide complexes.
PCT/US1995/003311 1994-03-16 1995-03-16 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens WO1995024923A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US08/704,727 US6048530A (en) 1994-03-16 1995-03-16 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
AT95913733T ATE286744T1 (en) 1994-03-16 1995-03-16 STRESS PROTEIN PEPTIDE COMPLEXES AS PROPHYLACTIC AND THERAPEUTIC VACCINES AGAINST INTRACELLULAR PATHOGENS
EP19950913733 EP0750513B1 (en) 1994-03-16 1995-03-16 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
AU21009/95A AU701732B2 (en) 1994-03-16 1995-03-16 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
DK95913733T DK0750513T3 (en) 1995-03-16 1995-03-16 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
DE1995633920 DE69533920T2 (en) 1994-03-16 1995-03-16 Stress protein peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
JP52418795A JPH10501520A (en) 1994-03-16 1995-03-16 Stress protein-peptide complex as a vaccine for prevention and treatment of intracellular pathogens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/210,421 US5961979A (en) 1994-03-16 1994-03-16 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US210,421 1994-03-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/210,421 Continuation-In-Part US5961979A (en) 1994-03-16 1994-03-16 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08/704,727 A-371-Of-International US6048530A (en) 1994-03-16 1995-03-16 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US09/412,420 Continuation US6455503B1 (en) 1994-03-16 1999-10-05 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens

Publications (2)

Publication Number Publication Date
WO1995024923A2 WO1995024923A2 (en) 1995-09-21
WO1995024923A3 true WO1995024923A3 (en) 1995-10-12

Family

ID=22782837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/003311 WO1995024923A2 (en) 1994-03-16 1995-03-16 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens

Country Status (10)

Country Link
US (5) US5961979A (en)
EP (2) EP0750513B1 (en)
JP (1) JPH10501520A (en)
AT (1) ATE286744T1 (en)
AU (1) AU701732B2 (en)
CA (1) CA2185651A1 (en)
DE (1) DE69533920T2 (en)
ES (1) ES2236705T3 (en)
PT (1) PT750513E (en)
WO (1) WO1995024923A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212378T1 (en) 1993-06-04 2002-02-15 Whitehead Biomedical Inst STRESS PROTEINS AND THEIR USE
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6761892B1 (en) * 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) * 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
WO1997006828A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
US6719974B1 (en) * 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
CA2265935C (en) 1996-09-20 2006-09-05 The University Of New Mexico Heat shock protein complexes
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
ES2258796T3 (en) * 1996-11-26 2006-09-01 Stressgen Biotechnologies Corporation FUSION PROTEINS CONTAINING STRESS PROTEINS TO INDUCE IMMUNE RESPONSES.
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
CA2282426A1 (en) * 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
BE1011033A6 (en) * 1997-03-05 1999-04-06 Univ Bruxelles PHARMACEUTICAL AND / OR FOOD COMPOSITION FOR THE TREATMENT OF CONDITIONS RELATED TO A GRAFT REJECTION, AN ALLERGIC OR AUTOIMMUNE REACTION OR CANCER.
US6709672B2 (en) 1997-03-05 2004-03-23 Biotech Tools S.A. Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
KR20060111731A (en) * 1997-08-05 2006-10-27 스트레스젠 바이오테크놀러지스 코포레이션 Immune responses against hpv(human papillomavirus) antigens elicited by compositions comprising a fusion protein comprising an hpv antigen and a stress protein
AU761432B2 (en) * 1997-10-31 2003-06-05 Sloan-Kettering Institute For Cancer Research Conjugate heat shock protein-binding peptides
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
ATE359084T1 (en) 1998-02-20 2007-05-15 Univ Miami MODIFIED HEAT SHOCK PROTEIN/PEPTIDE ANTIGEN COMPLEX
AU2004200711B2 (en) * 1998-08-19 2005-11-10 Immunobiology Limited Vaccine Comprising Cytokine-Induced Heat Shock Proteins (HSP)
GB9818133D0 (en) * 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
US6495347B1 (en) 1999-07-08 2002-12-17 Stressgen Biotechnologies Corporation Induction of a Th1-like response in vitro
AU2005204321B2 (en) * 1999-08-19 2008-07-10 Immunobiology Limited Vaccines from Infectious Agents
AUPQ233799A0 (en) * 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
GB9919734D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
US7378096B2 (en) * 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
JP2003510334A (en) 1999-09-30 2003-03-18 コリクサ コーポレイション Stress protein compositions and methods for prevention and treatment of cancer and infectious diseases
DE60042704D1 (en) 2000-01-14 2009-09-17 Whitehead Biomedical Inst INDUCTION OF CYTOTOXIC LYMPHOCYTES BY HOT SHOCK PROTEIN FUSION PROTEIN DEPENDS FROM THE ATP BINDING DOMAIN IN HSP AND IS CD4 + INDEPENDENT
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
AU2001246393A1 (en) * 2000-03-31 2001-10-08 Vaccine Chip Technology Aps Immunostimulating properties of a fragment of tgf-beta
US20030190322A1 (en) * 2000-03-31 2003-10-09 Peter Kaastrup Immunostimulating properties of a fragment of tgf-beta
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
AU6669401A (en) 2000-06-02 2001-12-11 Univ Connecticut Health Ct Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
HUP0301308A3 (en) * 2000-06-26 2010-01-28 Nventa Biopharmaceuticals Corp Human papilloma virus treatment
PT1319064E (en) * 2000-07-27 2008-02-29 Novartis Vaccines & Diagnostic Gsk3 polypeptides
EP1652856A1 (en) 2000-08-09 2006-05-03 The Regents of The University of California San Diego Stress proteins-derived peptides and method of use thereof
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
GB0021757D0 (en) * 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
CA2422867A1 (en) * 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
RU2295536C2 (en) 2001-02-05 2007-03-20 Стрессджен Байотекнолоджиз Корп. Composition based on hepatitis b virus (hbv) protein and stress protein and uses thereof
US6855925B2 (en) * 2001-02-14 2005-02-15 Picoliter Inc. Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
US6673351B1 (en) 2001-03-16 2004-01-06 Astralis, Llc Compositions and methods for the treatment and clinical remission of psoriasis
US20040241168A1 (en) * 2001-03-16 2004-12-02 O'daly Jose A. Compositions and methods for the treatment and clinical remission of psoriasis
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
US6875849B2 (en) 2001-05-01 2005-04-05 Arizona Board Of Regents Of Behalf Of The University Of Arizona Methods of recovering chaperone proteins and complexes thereof
JP4384489B2 (en) * 2001-08-20 2009-12-16 ユニバーシティー オブ コネティカット ヘルス センター Method for preparing a composition comprising a heat shock protein or α-2-macroglobulin useful for the treatment of cancer and infectious diseases
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
WO2003029419A2 (en) * 2001-10-01 2003-04-10 Duke University Three dimensional structure of crystalline grp94 binding domain, and its methods of use
US20030194409A1 (en) * 2002-01-17 2003-10-16 Rothman James E. Conjugate heat shock protein-binding peptides
WO2003061684A2 (en) * 2002-01-24 2003-07-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Tumour treatment compositions comprising hsp70 and tumour necrosis factor
US20030216315A1 (en) * 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
JP2005530487A (en) * 2002-02-28 2005-10-13 アンティジェニクス インコーポレーテッド Methods and products based on oligomerization of stress proteins
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003090686A2 (en) * 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
RU2375077C2 (en) * 2002-05-02 2009-12-10 Юниверсити Оф Коннектикут Хелт Сентер Application of heat-shock proteins for improving effectiveness of antibody therapies
ES2353753T3 (en) 2002-08-16 2011-03-04 Glycotope Gmbh PROCEDURE FOR THE PRODUCTION OF LISTS OF TUMOR CELLS INDUCED BY TEMPERATURE FOR USE AS IMMUNOGEN COMPOUNDS.
AU2003287048A1 (en) * 2002-10-07 2004-05-04 Antigenics, Inc. Heat shock protein binding fragments of cd91, and uses thereof
CA2503457A1 (en) * 2002-10-25 2004-05-06 University Of Connecticut Health Center Apparatus and method for immunotherapy of a cancer through controlled cell lysis
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
JP2006514088A (en) * 2003-02-20 2006-04-27 ユニバーシティー オブ コネティカット ヘルス センター Use of a composition comprising heat shock protein or α-2-macroglobulin in the treatment of cancer and infectious diseases
EP1603936B1 (en) 2003-02-28 2012-04-11 Agenus Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
PL1654353T3 (en) * 2003-08-18 2013-11-29 Glycotope Gmbh Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
CA2538794C (en) 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
EP2145896A3 (en) * 2003-11-12 2010-03-31 Alfa Biogene International B.V. Recovery of a heat shock protein
WO2007050978A2 (en) * 2005-10-29 2007-05-03 University Of Connecticut Methods for the elimination of pathogens and other particulate agents
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
PL2073842T3 (en) 2006-09-10 2015-06-30 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (en) * 2006-11-10 2015-06-30 Glycotope Gmbh Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
EP2102239B1 (en) * 2006-11-30 2012-04-25 Research Development Foundation Improved immunoglobulin libraries
AU2009223838B2 (en) 2008-03-03 2012-07-26 The University Of Miami Allogeneic cancer cell-based immunotherapy
GB0816242D0 (en) * 2008-09-05 2008-10-15 Immunobiology Ltd Method of purifying protien complexes
CN102223894A (en) * 2008-11-21 2011-10-19 迈阿密大学 Hiv/siv vaccines for the generation of mucosal and systemic immunity
WO2010115118A2 (en) 2009-04-03 2010-10-07 Antigenics, Inc. Methods for preparing and using multichaperone-antigen complexes
GB0910591D0 (en) 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2797059A1 (en) * 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
GB201104897D0 (en) 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2686313T3 (en) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganisms that carry a tumor antigen
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
RU2495565C1 (en) * 2012-10-03 2013-10-20 Игорь Николаевич Габриэль Method to stimulate growth and to improve resistance of farm animals
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
KR20170109582A (en) 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 Vector co-expression vaccine and co-stimulatory molecule
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
AU2016260540B2 (en) 2015-05-13 2021-01-07 Agenus Inc. Vaccines for treatment and prevention of cancer
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
KR102182941B1 (en) * 2017-11-03 2020-11-25 건국대학교 산학협력단 Methods for RNA Extraction and Cattles Stress Analysis
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN117815404A (en) 2018-05-18 2024-04-05 第一三共株式会社 anti-MUC 1 antibody-drug conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018146A2 (en) * 1992-03-04 1993-09-16 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Proteins forming complexes with chaperones and ligands thereof, fragments thereof, preparation thereof and biological uses thereof
WO1994003208A1 (en) * 1992-07-30 1994-02-17 Yeda Research And Development Company Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
WO1994029459A1 (en) * 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
DE68924162T2 (en) * 1988-06-15 1996-04-25 Whitehead Biomedical Inst STRESS PROTEINS AND USES THEREFOR.
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) * 1990-07-25 1990-09-12 Burnie James P Medicaments
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
GB9200949D0 (en) * 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
WO1993018150A1 (en) * 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (en) * 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
HUT70972A (en) * 1992-03-09 1995-11-28 Ist Naz Stud Cura Dei Tumori Protein compound capable of inhibiting tumoral growth
WO1993021529A1 (en) * 1992-04-14 1993-10-28 Duke University Method of detecting tumors containing complexes of p53 and hsp70
WO1994003599A1 (en) * 1992-08-04 1994-02-17 Sagami Chemical Research Center HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5680984A (en) 1994-05-13 1997-10-28 Matsushita Electric Industrial Co., Ltd. Apparatus and method for mounting soldering balls onto surfaces of electronic components
WO1997006828A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
WO1997026910A2 (en) * 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumour vaccine for immunotherapy of malignant tumours
DE19602985A1 (en) * 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumour vaccine for treatment of, e.g., carcinoma melanoma or leukaemia
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
GB0004547D0 (en) 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018146A2 (en) * 1992-03-04 1993-09-16 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Proteins forming complexes with chaperones and ligands thereof, fragments thereof, preparation thereof and biological uses thereof
WO1994003208A1 (en) * 1992-07-30 1994-02-17 Yeda Research And Development Company Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
WO1994029459A1 (en) * 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. BARRIOS ET AL.: "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming.", EUR. J. IMMUNOL., vol. 22, pages 1365 - 1372 *
CHEMICAL ABSTRACTS, vol. 121, no. 23, 5 December 1994, Columbus, Ohio, US; abstract no. 271089a, SRIVASTAVA P.K. AND UDONO H.: "Heat-shock protein-peptide complexes in cancer immunotherapy." page 12; *
CURR. OPIN. IMMUNOL., vol. 6, no. 5, pages 728 - 732 *
P. K. SRIVASTAVA: "Heat shock proteins in immune response to cancer: The Fourth Paradigm.", EXPERIENTIA, vol. 50, pages 1054 - 1060 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same

Also Published As

Publication number Publication date
US20030165516A1 (en) 2003-09-04
US6455503B1 (en) 2002-09-24
JPH10501520A (en) 1998-02-10
US20030165515A1 (en) 2003-09-04
DE69533920D1 (en) 2005-02-17
AU701732B2 (en) 1999-02-04
PT750513E (en) 2005-04-29
EP0750513A1 (en) 1997-01-02
DE69533920T2 (en) 2005-12-01
ES2236705T3 (en) 2005-07-16
US6048530A (en) 2000-04-11
AU2100995A (en) 1995-10-03
CA2185651A1 (en) 1995-09-21
EP0750513B1 (en) 2005-01-12
US5961979A (en) 1999-10-05
WO1995024923A2 (en) 1995-09-21
ATE286744T1 (en) 2005-01-15
EP1604684A1 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
WO1995024923A3 (en) Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
FR2727689B1 (en)
GR3030568T3 (en) Inducing cytotoxic t lymphocyte responses.
GB2075343B (en) Improvements to methods for preparing galencial preparation with delayed action and programmed release and galenical preparations for drugs obtained thereby
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
AU4519089A (en) Device for aiding in preparation of intravenous therapy
CA2033640A1 (en) Vaccines against cancer and infectious diseases
NZ228564A (en) Corticosteroid-containing skin care composition for use as moisturiser: preparation thereof
WO1995011008A3 (en) Methods and compositions for microencapsulation of adjuvants
HK26294A (en) Stabilization of the preservative thiomersal in ophthalmic pharmaceutical compositions
AU3847589A (en) Procedure and container for the preparation and storage of platelet concentrates
WO1999050303A3 (en) Immune response modulator alpha-2 macroglobulin complex
USD259058S (en) Knee brace
AU7472191A (en) Therapeutic composition containing a phenol compound and propolis useful against lipidic capside viruses, especially the herpes viruses
AU8563891A (en) Medicine pack with flip top closure
FI932759A0 (en) Enhancement of IL-4 For the purpose of vaccinia immunogenic generic immunoreaction
MY128929A (en) Vaccine against hepatitis a and hepatitis b
WO1989000166A3 (en) Growth hormone related peptide
AU554859B2 (en) Polymerized albumin vaccine
USD262954S (en) Astrology chart display
CA2011050A1 (en) Human monocyte-machrophage-csf preparations
FR2690839B1 (en) VACCINATION ASSEMBLY AGAINST RABBIT INTEROTOXEMIA AND VACCINE PACKAGED FOR USE IN THIS ASSEMBLY.
USD263954S (en) Headgear to be used in relaxation therapy
USD324571S (en) Combined extendible and contractible massage table
GB2060384A (en) Prophylactic and curative medicine for cirrhotic liver

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: CA

Ref document number: 2185651

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: US

Ref document number: 1996 704727

Date of ref document: 19960916

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2185651

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995913733

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995913733

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08704727

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 1995913733

Country of ref document: EP